Moderna and Pfizer COVID-19 vaccine protection declines over time
Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on Friday suggest that protection from their respective COVID-19 vaccines wanes over time. This comes as the FDA consider the approval of a booster programme in the US.
Moderna shared new data about its vaccine on Wednesday. In addition to the jab being highly effective against new strains, the company released data from their Phase III COVE study suggesting that a booster dose of the vaccine will support greater efficacy for the population.
Moderna and Pfizer COVID-19 vaccine protection declines over time | Pharmafile
